Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,119 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

NCT04042376

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • The First Hospital of Jilin University Changchun, China
  • First affiliated Hospital of Zhejiang University Hangzhou, China
  • Institute of Hematology and Blood Diseases Hospital Tianjin, China
  • Wuhan Union Hospital Wuhan, China
View Trial Details
Completed

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memoral Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

NCT04062448

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Kameda Medical Center Chiba, Japan
  • National Cancer Center Hospital Chūōku, Japan
  • National Hospital Organization Kumamoto Medical Center Kumamoto, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Japan
View Trial Details
Completed

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

NCT03941860

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
  • Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California, United States
  • Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California, United States
View all 222 locations
View Trial Details
Completed

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04436107

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
View Trial Details
Completed

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

NCT03113422

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins Baltimore, Maryland, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT02519452

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Atlanta, Georgia, United States
  • New York, United States
  • Charlotte, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 108 San Francisco, California, United States
  • University of California - San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
  • Local Institution - 103 Atlanta, Georgia, United States
View all 48 locations
View Trial Details

Related conditions